

1 **Influence of ethnicity and consanguinity on the genetic architecture of Hypertrophic**
2 **Cardiomyopathy: insights from an understudied population**

3 **Keywords:** Egyptian Collaborative Cardiac Genomics Project, homozygosity, NGS

4
5 Mona Allouba,^{1,2,11,*} Roddy Walsh,^{2,3,11} Alaa Afify,¹ Mohammed Hosny,^{1,4} Sarah Halawa,¹ Aya
6 Galal,¹ Mariam Fathy,¹ Pantazis I. Theotokis,² Ahmed Boraey,¹ Amany Ellithy,¹ Rachel
7 Buchan,^{2,5} Risha Govind,^{2,5,6,7} Nicola Whiffin,^{2,5,8} Shehab Anwer,¹ Ahmed ElGuindy,¹ James
8 S. Ware,^{2,5,9,12} Paul J.R. Barton,^{2,5,9,12} Yasmine Aguib,^{1,2,12*} Magdi Yacoub,^{1,2,10,12*}

9
10 ¹ Aswan Heart Centre, Aswan, Magdi Yacoub Heart Foundation, Egypt
11 ² National Heart and Lung Institute, Imperial College London, London, United Kingdom
12 ³ Department of Experimental Cardiology, Amsterdam UMC, the Netherlands
13 ⁴ Cardiology Department, Kasr Al Aini Medical School, Cairo University
14 ⁵ Royal Brompton & Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust,
15 London, United Kingdom
16 ⁶ Present affiliation: Institute of Psychiatry, Psychology and Neuroscience, King's College
17 London, London, United Kingdom
18 ⁷ Present affiliation: National Institute for Health Research (NIHR) Biomedical Research
19 Centre, South London and Maudsley NHS Foundation Trust and King's College London,
20 London, United Kingdom
21 ⁸ Present affiliation: Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3
22 7BN, United Kingdom
23 ⁹ MRC London Institute of Medical Sciences, Imperial College London, London, United
24 Kingdom
25 ¹⁰ Harefield Heart Science Centre, United Kingdom

26
27
28
29
30
31
32
33
34
35
36
37

¹¹ These authors contributed equally

¹² Senior author

*Correspondence: monaallouba@gmail.com, yaguib@gmail.com, m.yacoub@imperial.ac.uk
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

38

39 **Abstract**

40 Hypertrophic cardiomyopathy (HCM) is an inherited cardiac condition characterized by
41 phenotypic heterogeneity that could partly be explained by the variability in genetic variants
42 contributing to disease. Accurate interpretation of these variants constitutes a major challenge
43 for diagnosis and implementing precision medicine, especially in understudied populations.
44 Here, we leverage ancestry-matched Egyptian patients (n=514) and deeply-phenotyped
45 controls (n=400) to accurately define the genetic architecture of HCM. We also compare HCM
46 variation between Egyptian and predominantly European patients to identify genetic features
47 unique to consanguineous populations in Middle East and North Africa (MENA), which are
48 likely to represent important contributors to disease. We report a higher prevalence of
49 homozygous variants in Egyptian patients (4.1% vs 0.1%, $p\text{-value}=2\times 10^{-7}$), with variants in the
50 minor HCM genes *MYL2*, *MYL3* and *CSRP3* more likely to present in homozygosity than the
51 major genes (*MYH7*, *MYBPC3*), suggesting that these variants are less penetrant in
52 heterozygosity. Biallelic variants in the recessive HCM gene *TRIM63* were detected in 2.1%
53 of patients (5-fold greater than European patients), highlighting the importance of recessive
54 inheritance/genes in consanguineous populations. Finally, significantly fewer rare variants
55 detected in Egyptian HCM patients could be classified as (likely) pathogenic compared to
56 Europeans (40.8% vs. 61.6%, $p\text{-value}=1.6\times 10^{-5}$) due to the underrepresentation of MENA
57 populations in current HCM databases. This proportion increased to 53.8% after incorporating
58 methods that compare variant frequencies between Egyptian patients and controls. Together,
59 our findings demonstrate that studying consanguineous populations reveals novel insights
60 with relevance to genetic testing and our understanding of the genetic architecture of HCM.

61

62

63

64

65

66 **Introduction**

67 Hypertrophic cardiomyopathy (HCM [MIM: 192600]) is a common inherited cardiac condition
68 affecting at least 1:500 in the general population ^{1,2}. It is defined by left ventricular hypertrophy
69 (LVH) in the absence of other identifiable cardiac or systemic causes. Since its first description
70 in 1958, HCM has been considered as a highly heterogenous disease with regards to mode
71 of inheritance, phenotype and genotype ³⁻⁵. The genetic etiology of HCM is largely attributed
72 to variation in genes that encode components of the contractile apparatus (sarcomere) in
73 cardiac muscle cells.

74

75 Large HCM datasets from the Sarcomeric Human Cardiomyopathy Registry (SHaRe) and
76 other diverse ancestral HCM populations have provided strong evidence supporting disease-
77 associated, long-term adverse clinical outcomes, including mortality ⁶⁻¹¹. With respect to
78 genotype, SHaRe demonstrated that patients with pathogenic sarcomere variants had an
79 earlier onset of disease and were at a higher risk of developing adverse clinical outcomes ¹⁰.
80 Given the interplay between genetics and disease progression, these patients may benefit
81 from effective treatments that delay or prevent HCM-related complications provided these
82 pathogenic variants are well characterized ^{10,12}. Although immense progress has been made
83 in elucidating the genetic determinants of HCM, much remains to be explored including
84 genetic-, environmental- and epigenetic factors influencing disease penetrance and
85 expressivity. Also, the rapid integration of genetic testing into everyday clinical practice has
86 resulted in the identification of a large number of variants of uncertain significance, which
87 cannot be acted upon clinically ^{10,13,14}. This issue is more evident in underrepresented
88 populations, who are more likely to receive inconclusive genetic testing results, compared to
89 well-studied European-ancestry HCM patients ¹⁵. Therefore, extending genomic research to
90 diverse ancestral populations will not only reduce health disparities as we move towards
91 precision-based HCM patient management but may also enhance variant interpretation for

92 diagnosis, and provide novel genetic and mechanistic insights into the disease. For example,
93 we have recently reported the identification of a new class of HCM pathogenic variants in
94 *MYH7*, which was enriched in Egyptian patients over ancestry-matched controls and absent
95 from large-scale HCM patients of predominantly European ancestry^{16–18}.

96
97 The aim of this study is to define the genetic architecture of HCM in the previously
98 understudied Egyptian population that is known to have a high rate of consanguinity^{19,20}. This
99 study provides, to our knowledge, the largest and most comprehensive analysis of HCM in the
100 Middle East and North Africa (MENA) region to date. We leverage a prospective Egyptian
101 HCM cohort and an ancestry-matched, Egyptian healthy volunteer control cohort with
102 comprehensive cardiovascular phenotyping, to define the genetic architecture of HCM in
103 Egypt. In addition, we compare genetic data between Egyptian and well-characterized patients
104 of predominantly European ancestry to identify genetic features unique to consanguineous
105 populations of MENA ancestry which are likely to be important contributors of HCM.

106

107 **Methods**

108 **Study population**

109 **Egypt HCM cohort**

110 A prospective cohort of unrelated HCM patients (n=514) was recruited to the Aswan Heart
111 Centre (AHC), Egypt as part of the Egyptian Collaborative Cardiac Genomics (ECCO-GEN)
112 Project and the National HCM Registry. This cohort is hereafter referred to as Egypt HCM.
113 Clinical diagnosis of HCM was confirmed by echocardiography and/or Cardiac Magnetic
114 Resonance (CMR) imaging.

115

116 **UK HCM cohort**

117 A prospective cohort of HCM patients of predominantly European ancestry (n=684) was
118 recruited by the NIHR Cardiovascular Biomedical Research Unit at the Royal Brompton

119 Hospital (RBH), London ²¹. This cohort is hereafter referred to as UK HCM. HCM diagnosis
120 was confirmed with CMR.

121

122 **Egypt control cohort**

123 Egyptian healthy volunteers (n=400) were recruited from across the country as part of the
124 Egyptian Collaborative Cardiac Genomics (ECCO-GEN) Project aiming to study local genetic
125 variation in 1000 healthy individuals ¹⁷. All volunteers underwent detailed cardiovascular
126 phenotyping, including clinical examination, 12-lead electrocardiogram, and CMR to confirm
127 absence of CVD. This cohort is hereafter referred to as Egypt control.

128

129 **UK control cohort**

130 UK healthy volunteers (n=1,054) of predominantly European ancestry were recruited
131 prospectively via advertisement for the UK Digital Heart Project at Imperial College London ²².
132 All volunteers, denoted hereafter as UK controls, underwent CMR to confirm the absence of
133 cardiac disease.

134 Participants from all four cohorts provided informed consent and were approved by their local
135 research ethics committees.

136

137 **Gene selection:**

138 DNA samples from the above-mentioned case and control cohorts were sequenced on
139 Illumina platforms (Miseq, Nextseq or Hiseq) and a subset of these on Life Technologies
140 SOLiD 5500xl using cardiac gene panels including the TruSight Cardio Sequencing kit ²³. The
141 number of HCM patients and controls from the Egypt and UK cohorts analyzed for each gene
142 are depicted in Supplementary Table 1. Thirteen validated autosomal dominant HCM genes,
143 including sarcomere-encoding (*ACTC1* (MIM: 102540), *MYBPC3* (MIM: 600958), *MYH7*
144 (MIM:160760), *MYL2* (MIM: 160781), *MYL3* (MIM: 160790), *TNNC1* (MIM: 191040), *TNNI3*
145 (MIM: 191044), *TNNT2* (MIM: 191045) and *TPM1* (MIM: 191010)) and non-sarcomere-
146 encoding genes (*PLN* (MIM: 172405), *ACTN2* (MIM: 102573), *CSRP3* (MIM: 600824), *JPH2*

147 (MIM: 605267)) were analyzed^{21,24,25}. Genes, which have been previously shown to account
148 for less than 5% of HCM cases were defined in this work as “minor” genes¹⁸. *MYH7* and
149 *MYBPC3* were defined here as “major” genes as they account for over 70% of identified
150 pathogenic variants in HCM²⁶. Separately, biallelic variants in the recently implicated
151 recessive HCM gene *TRIM63* (MIM: 606131) were evaluated. Some genes recently identified
152 as rarer causes of HCM (*ALPK3* (MIM: 617608), *FHOD3* (MIM: 609691), *FLNC* (MIM: 102565)
153 were not included on the gene panels used in this study.

154

155 **Rare variant filtering and classification**

156 Rare variants in validated HCM genes were defined as having a filtering allele frequency (FAF)
157 of $\leq 4 \times 10^{-5}$ in gnomAD (v2.1.1) based on the statistical framework proposed by Whiffin *et al.*,
158 2017²⁷. Variants were annotated by CardioClassifier based on rules defined by the American
159 College of Medical Genetics and Genomics/Association of Molecular Pathology (ACMG-AMP)
160 as Pathogenic (P), Likely Pathogenic (LP) and Uncertain Significance (VUS) (full details in
161 Supplementary Methods)^{28,29}. Detailed lists of all rare variants observed in the Egyptian and
162 UK HCM and control cohorts are provided in Supplementary Tables 2-5.

163

164 **Comparison of the genetic landscape of HCM between Egypt and UK HCM cohorts**

165 First, the genetic architecture of the HCM in the Egyptian population was assessed by
166 comparing the frequency of rare variation in validated HCM genes between ancestry-matched
167 patients and controls. Second, the genetic landscape of HCM was compared between the
168 Egypt and UK HCM cohorts using their respective population-matched controls. For each
169 gene, the excess of rare variants in the Egypt HCM cohort over the Egypt control cohort was
170 compared with the excess of rare variants in the UK cohort over UK controls (Egypt HCM_{Control}
171 excess vs. UK HCM_{Control} excess). Third, the proportion of genotype-positive patients (i.e.,
172 those carrying rare variants) attributable to each HCM gene was compared between the Egypt
173 and UK HCM cohorts.

174 **Comparison of the proportion of clinically actionable variants between the Egypt and**
175 **UK HCM cohorts**

176 The proportion of clinically actionable variants (i.e., P and LP) was evaluated in the Egypt
177 HCM cohort by dividing the number of patients with P/LP variants by the total number of
178 patients with rare variants in validated HCM genes. For patients with multiple hits (refer to
179 Supplementary Tables 6 and 7), the variant with the highest pathogenicity was prioritized (i.e.,
180 P then LP then VUS). The proportion of clinically actionable variants was then compared
181 between the Egypt and UK HCM cohorts.

182

183 **Application of the new Etiological Fraction (EF)-based American College of Medical**
184 **Genetics and Genomics/Association or Molecular Pathology (ACMG-AMP) rule on rare**
185 ***MYH7* missense variants**

186 The effect of the recently proposed EF-based ACMG/AMP rules by Walsh *et al.*, 2019 on the
187 yield of actionable *MYH7* missense variants (i.e. P and LP) identified in the Egypt HCM cohort
188 was assessed¹³.

189 First, we evaluated whether the regional distributions of pathogenic and benign variation in
190 *MYH7*, previously observed in European individuals, is also observed in Egyptians. The
191 frequency of rare missense *MYH7* variants in the predefined patient-enriched HCM cluster
192 (residues: 167-931) was calculated¹³. The distribution of rare missense *MYH7* variants in the
193 Egypt HCM and control cohorts and was visualized using the TrackViewer package (v 1.22.1)
194 in R statistical environment (v 3.6.3). This was further compared with the previously published
195 cohort of >6,000 HCM patients from Partners Laboratory of Molecular Medicine and Oxford
196 Medical Genetics Laboratory (denoted here as LMM/OMGL)¹⁸. Second, the odds ratio (OR)
197 and etiological fraction (EF) ($EF = (OR-1)/OR$) for this cluster were calculated using the Egypt
198 control cohort as the reference control population.

199

200 *MYH7* missense variants were classified as per the adopted new EF-based PM1_strong rule,
201 which is activated if these variants are located in a protein region with $EF \geq 0.95$

202 Results

203 Cohort characteristics

204 The Egypt HCM cohort comprised 514 patients (67% male, 33% female; full details in
205 Supplementary Table 8). Consanguinity was reported in 28.4% of Egyptian patients. Notably,
206 UK patients (n=684) were ca. 20 years older (mean onset age 55.5 ± 15.5 years vs. 34.7 ± 17.4
207 years, $p\text{-value} < 2.2 \times 10^{-16}$), presented with less severe hypertrophy (LVMWT: 18.9 ± 4.4 mm vs.
208 23.6 ± 7 mm, $p\text{-value} = 4.9 \times 10^{-15}$) and showed a lower incidence of left ventricular outflow tract
209 obstruction (LVOTO) (24%) compared to Egyptian patients (36% vs. 73%, $p\text{-value} < 2.2 \times 10^{-16}$).
210 A summary of the demographic- and cardiac characteristics of the Egypt and UK HCM cohorts
211 with available data is outlined in Table 1.

212

213 **Table 1: Demographic and cardiac characteristics of Egypt and UK HCM cohorts**

General characteristics	Egypt HCM n(%)	UK HCM n(%)	p-value
Demographics			
Age (years) (mean (sd))	34.7 ± 17.4	55.5 ± 15.5	$< 2.2 \times 10^{-16}$
Male gender n(%)	345 (67.3%)	473 (73.4%)	0.02
Offspring of Consanguineous Marriage*	99 (28.4%)	N/A	N/A
FH of HCM	111 (25.1%)	127 (24.5%)	0.88
FH of SCD	78 (17.6%)	116 (25.2%)	0.01
Cardiac Characteristics			
LVMWT (mm)** (mean (sd))	23.6 ± 7	18.9 ± 4.4	4.9×10^{-15}
Extreme LVMWT (>30mm)	54 (17.5%)	8 (1.3%)	$< 2.2 \times 10^{-16}$
LVOTO (≥ 30 mm Hg)	220 (72.8%)	223 (36.1%)	$< 2.2 \times 10^{-16}$
LVEF (%)** (mean (sd))	71.5 ± 13.3	74.3 ± 8.5	0.004
Myectomy	168 (51.5%)	N/A	N/A
ICD implantation	7 (2.7%)	N/A	N/A

214 *Consanguinity (self-reported) was defined as first-cousin marriage. FH: Family History, SCD: Sudden
215 Cardiac Death, LVMWT: Left Ventricular Maximal Wall Thickness, LVOTO: Left Ventricular Outflow
216 Tract Obstruction, LVEF: Left Ventricular Ejection Fraction, ICD: Implantable Cardioverter Defibrillator.
217 **LVMWT and LVEF were measured in the Egypt HCM and UK HCM cohorts by echocardiography and
218 CMR, respectively.
219

220 Differences in the genetic architecture of HCM between Egyptian- and UK patients

221 In order to evaluate the genetic architecture of HCM in Egypt, we compared the burden of rare
222 variation ($\text{gnomAD}_{\text{popmax}} \text{FAF} < 4 \times 10^{-5}$) in validated HCM genes between Egyptian patients and

223 controls (Figure 1A, left). The inclusion of ancestry-matched controls into this analysis enabled
224 us to address the potential bias introduced by defining rare variants using gnomAD, which has
225 minimal representation from the MENA region (Supplementary Figure 1).

226
227 In addition, we compared the genetic landscape of HCM between the Egypt and UK HCM
228 cohorts (using their respective population-matched controls), to directly compare the excess
229 burden of rare variants in HCM-associated genes in each cohort (labelled as Egypt HCM_{Control}
230 excess and UK HCM_{Control} excess) (Figure 1A, right). A higher overall excess burden of rare
231 variation was observed in the Egypt HCM cohort compared to UK HCM (52.7% vs. 32.0%)
232 (Figure 1A), with 1.6-fold more Egyptian patients carrying rare variants compared to UK HCM
233 (Figure 1B). We then performed a secondary analysis comparing the proportion of genotype-
234 positive patients (i.e., those carrying rare variants) attributable to each HCM gene between
235 the Egypt and UK HCM cohorts (Figure 1C).

236
237 As expected, rare variants in both *MYH7* and *MYBPC3* accounted for the majority of rare
238 variation in both the Egypt and UK HCM cohorts (Table 2). *MYBPC3* non-truncating variants
239 and *PLN* variants accounted for a higher proportion of genotype-positive patients in the UK
240 HCM cohort compared to Egyptian patients (*MYBPC3*: 26.9% vs. 13.7% and *PLN*: 0.92% vs.
241 0%) (Table 2). In contrast, *MYH7* truncating variants accounted for a higher proportion of
242 genotype-positive patients in the Egypt HCM cohort, which is explained by the recurrent
243 variant c.5769delG [p.Ser1924AlafsTer9]. This variant was present in 3.3% of Egypt HCM
244 patients and we recently showed that it causes HCM by introducing a distal premature
245 termination codon, which escapes nonsense mediated decay resulting in the expression of an
246 abnormal protein¹⁶. Several recurrent truncating variants in *MYBPC3* were also detected, with
247 two of these (c.1516delG [p.Asp506ThrfsTer7] (0.97%, n=5) and c.534_541delGGCCGGCG
248 [p.Ala179GlnfsTer59] (1.36%, n=7)) likely to be Egyptian/North African specific founder
249 variants. *MYBPC3* founder variants have similarly been reported in numerous regions³⁰.

250

251 Due to the limited number of observed variants, HCM genes encoding components of the thin
252 filament (*ACTC1*, *TNNC1*, *TNNI3*, *TNNT2* and *TPM1*) and myosin light chain (MLC: *MYL2*
253 and *MYL3*) were combined into groups based on their similar function. While rare variation in
254 thin filament genes accounted for a relatively higher proportion of genotype-positive patients
255 in the UK HCM cohort compared to Egypt HCM (12.3% vs. 6.6%), non-truncating variants in
256 MLC genes accounted for a higher proportion of genotype-positive patients in the Egypt HCM
257 cohort (9.96% vs. 2.28%) (Table 2).

258

259 Six distinct variants were identified in each of *MYL2* (5 missense and 1 splice site) and *MYL3*
260 (6 missense) (Supplementary Table 2). Of these, three *MYL2* variants were recurrently
261 observed in Egyptian patients (c.173G>A [p.Arg58Gln] (n=2,0.39%), c.450G>T
262 [p.Leu150Phe] (n=3,0.58%) and c.278C>T [p.Ala93Val] (n=5, 0.97%)). In *MYL3* 3/6 missense
263 variants observed in Egyptian patients were also recurrent (c.460C>T [p.Arg154Cys]
264 (n=2,0.39%), c.518T>C [p.Met173Thr] (n=4,0.78%) and c.508G>C [p.Glu170Gln]
265 (n=6,1.17%)). With the exception of the known pathogenic *MYL2* p.Arg58Gln variant, these
266 recurrent variants were absent from both the UK HCM cohort and LMM/OMGL HCM cohorts.
267 Also, the *MYL2* variant p.Leu150Phe has not been previously reported whereas the other ten
268 MLC variants are currently classified as VUS in ClinVar.


269

270 For the non-sarcomeric HCM genes, rare variants in both *CSRP3* (truncating and non-
271 truncating) and *JPH2* (non-truncating) showed a nominal enrichment in the genotype-positive
272 Egypt HCM cohort compared to UK HCM (Table 2).

273

274 To explore why variants in some minor HCM genes (MLC, *CSRP3* and *JPH2*) seem to be
275 more prevalent in the Egypt HCM cohort compared to UK HCM , we then examined the effect
276 of consanguinity, and the frequency of homozygous variants, on this cohort.

277



278

279 **Figure 1: Enrichment of rare variation in HCM minor genes (MLC, CSRP3 & JPH2) in the Egypt**
 280 **HCM cohort vs. UK HCM. A)** The overall frequency of rare variants (gnomAD_{popmax} FAF $\leq 4 \times 10^{-5}$) in 13
 281 validated HCM genes was compared between Egypt and UK HCM patients and controls. A 1.6 fold
 282 greater excess burden (i.e. total case frequency – total control frequency) was observed in the Egypt
 283 HCM cohort, which should be accounted for with the direct gene comparisons (B). **B)** Population-
 284 matched patients vs. control comparison (Egypt HCM_{Control} excess and UK HCM_{Control} excess) of genetic
 285 variation between Egypt and UK cohorts for each HCM gene/gene class. C) Comparison of the
 286 proportion of genotype-positive patients (i.e., those carrying rare variants) per HCM gene confirms the
 287 enrichment of rare variants in the HCM minor genes MLC (MYL2 & MYL3), CSRP3 and JPH2 in
 288 Egyptians (as observed in Figure B). Truncating and non-truncating variants (Figures A & B) are shown
 289 in red and grey, respectively. *Thin filament: ACTC1, TNNC1, TNNI3, TNNT2, TPM1.*

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311 **Table 2: Comparison of population-matched patient versus control excess frequencies (left) and**
 312 **the proportion of genotype-positive patients between Egypt HCM and UK HCM cohorts (right)**
 313 **for sarcomeric- and other validated HCM genes**

Gene/Gene groups	Variant type	Excess of RV in patients vs. controls		Proportion of all G+	
		Egypt HCM _{Control} excess	UK HCM _{Control} excess	Egypt HCM G+ prop	UK HCM G+ prop
<i>MYH7</i>	Non-truncating	13.95%	9.68%	30.26%	32.88%
	Truncating	3.06%	0.01%	6.27%	0.91%
<i>MYBPC3</i>	Non-truncating	4.45%	6.73%	13.65%	26.94%
	Truncating	9.34%	5.41%	17.71%	16.89%
<i>Myosin light chain (MLC)</i>	Non-truncating	5.25%	0.26%	9.96%	2.28%
	Truncating	0.19%	0.00%	0.37%	0%
<i>Thin Filament</i>	Non-truncating	3.50%	3.38%	6.64%	12.33%
	Truncating	0.00%	-0.09%	0%	0%
<i>CSRP3</i>	Non-truncating	1.70%	0.49%	3.69%	1.83%
	Truncating	0.72%	0.00%	1.85%	0%
<i>JPH2</i>	Non-truncating	1.47%	0.29%	5.17%	1.37%
	Truncating	0%	0%	0%	0%
<i>ACTN2</i>	Non-truncating	-0.11%	0.51%	4.06%	3.65%
	Truncating	0.19%	0%	0.37%	0%
<i>PLN</i>	Non-truncating	0%	-0.23%	0%	0.46%
	Truncating	0%	0.15%	0%	0.46%

Comparison of the excess of rare ($FAF \leq 4 \times 10^{-5}$) variation in HCM patients over controls for Egypt and UK cohorts, grouped by gene/gene class and variant class (left). Note – the overall case excess across the validated HCM genes/gene classes is 1.6 times greater in the Egypt cohort (Figure 1A), therefore any comparisons for specific genes or gene classes between Egypt and UK cohorts should take this into account. The proportion of genotype-positive (i.e., those with rare variants) Egypt HCM and UK HCM patients per HCM gene is shown (left). RV: rare variants; G+: genotype-positive; prop: proportion.

314
 315
 316 **Higher burden of homozygous variants in the Egypt HCM cohort compared to UK HCM**

317 In the Egypt HCM cohort, 28% of patients reported to have consanguineous parents. This
 318 prompted us to evaluate the frequency of homozygous variants, both for rare variants
 319 ($FAF_{popmax} \leq 4.0 \times 10^{-5}$) and for low frequency variants sufficiently rare to cause biallelic disease
 320 ($FAF_{popmax} \leq 0.00126$)²⁷. The yield of homozygous variants was then compared with the UK
 321 cohort.

322 As expected, homozygous variants were significantly more common in Egyptian patients
 323 compared to UK, for both the rare (4.1% (n=21) vs. 0.1% (n=1), $p=2 \times 10^{-7}$) and low frequency
 324 (2.1% (n=11) vs. 0%, $p=8.5 \times 10^{-5}$) variants. Table 3 summarizes the homozygous variants
 325 observed in Egyptian patients. Homozygous variants in these genes were not observed in

326 either the Egypt or UK control cohorts. Among Egypt HCM patients carrying homozygous
327 variants, 31.3% reported not having consanguineous parents (i.e. first cousins), which may
328 indicate an underreporting of consanguinity or more distantly related patients.

329

330 Two Egyptian patients presented with homozygous *MYBPC3* truncating variants (c.1558G>T
331 [p.Glu520Ter] and c.1227-2A>G). Truncating variants in *MYBPC3* are known to lead to
332 severe, early-onset disease when expressed in homozygosity ³¹. The patient carrying the
333 nonsense variant p.Glu520Ter was indeed diagnosed with HCM at birth and died suddenly
334 before adolescence. In contrast, the patient carrying the c.1227-2A>G splice variant in
335 homozygosity presented with HCM in adulthood, although at a younger age and with more
336 severe hypertrophy (LVMWT: 27mm vs. 20mm) than the patient with the same variant in the
337 heterozygous state. Accordingly, this splice acceptor variant is predicted (by SpliceAI) to result
338 in an exon extension of 33 intronic bases into the *MYBPC3* transcript, which suggests that the
339 variant maintains the open reading frame and may therefore function as an inframe insertion
340 (Supplementary Figure 2).

341

342 Notably, homozygous variants were particularly enriched in three minor HCM genes (i.e. those
343 previously shown to account for less than 5% of HCM patients each in European populations)
344 - *CSRP3* and the MLC genes *MYL2* and *MYL3* ¹⁸ (Table 3). Therefore, we sought to compare
345 the relative contribution of homozygous variants across the HCM genes. The proportion of
346 rare homozygous variants was consistent across the major HCM genes, with 5-7% of variants
347 being homozygous in *MYH7*, *MYBPC3* and the thin filament genes (Table 4 and Figure 2).
348 This proportion could be regarded as a background homozygosity rate for dominant HCM
349 genes caused by the level of consanguinity present in the Egyptian population. In contrast the
350 MLC and *CSRP3* genes showed a substantially higher proportion of homozygous variants
351 (25.6% and 33.3%, respectively). It is worth mentioning that the increase in frequency of MLC
352 homozygous variants from 14.3% (using the rare frequency threshold) to 25.6% (using the
353 biallelic frequency threshold) was largely due to a recurrently observed low-frequency

354 (gnomAD_{popmax} FAF=4.4x10⁻⁵) *MYL3* variant c.530A>G [p.Glu177Gly] in the Egyptian cohort
355 (0.78%,n=4).

356

357 These findings suggest that, unlike the major HCM genes, rare variants in these minor genes
358 may be generally less penetrant in the heterozygous state. Evidence for an additive, rather
359 than a true recessive, model is supported by the fact that heterozygous variants in these genes
360 are also enriched in Egyptian patients compared to controls and that the vast majority of
361 previously reported pathogenic *CSRP3* and missense *MLC* variants have been associated
362 with autosomal dominant HCM. Taken together, these findings explain the relatively higher
363 proportion of rare variants in *MLC* and *CSRP3* genes observed in Egyptian patients compared
364 to UK (Figure 1), with high consanguinity rates enabling variants to occur in a more penetrant
365 homozygous state.

Table 3: Details of homozygous variants identified in the Egypt HCM cohort (n=514) compared to Egypt controls (n=400)

Gene	Variant type	cDNA variant	Protein variant	gnomAD FAF _{popmax}	Control hom freq (count)	Control het freq (count)	HCM hom case freq (count)	HCM het case freq (count)
A) Sufficiently rare variants (gnomAD FAF_{popmax} ≤ 0.00126) to cause mono allelic HCM								
MYH7	Missense	c.5122G>A	p.Glu1708Lys	0	0%	0%	0.19% (1)	0%
	Missense	c.4258C>T	p.Arg1420Trp	3.0x10 ⁻⁶	0%	0%	0.19% (1)	0.39% (2)
	Missense	c.3622G>C	p.Asp1208His	0	0%	0%	0.19% (1)	0.58% (3)
	Missense	c.1064C>T	p.Ala355Val	0	0%	0%	0.19% (1)	0%
	Missense	c.925G>A	p.Asp309Asn	1.1x10 ⁻⁵	0%	0%	0.19% (1)	0.78% (4)
	Frameshift*	c.5769delG	p.Ser1924AlafsTer9	0	0%	0%	0.19% (1)	3.11% (16)
MYBPC3	Missense	c.2908C>T	p.Arg970Trp	0	0%	0.25% (1)	0.19% (1)	0.39% (2)
	Missense	c.2458C>G	p.Arg820Gly	0	0%	0%	0.19% (1)	0%
	Inframe Deletion	c.2441_2443delA GA	p.Lys814del	0	0%	0%	0.19% (1)	0%
	Nonsense	c.1558G>T	p.Glu520Ter	0	0%	0%	0.19% (1)	0%
	Splice acceptor	c.1227-2A>G	-	0	0%	0%	0.19% (1)	0.19% (1)
MYL2	Missense	c.278C>T	p.Ala93Val	0	0%	0%	0.19% (1)	0.78% (4)
MYL3	Missense	c.508G>C	p.Glu170Gln	0	0%	0%	0.58% (3)	0.58% (3)
TNNI3	Missense	c.485G>T	p.Arg162Leu	0	0%	0%	0.19% (1)	0%
CSRP3	Splice acceptor	c.415-1G>C	-	0	0%	0%	0.19% (1)	0%
	Splice donor	c.414+1G>T	-	0	0%	0.25% (1)	0.58% (3)	0.19% (1)
	Missense	c.365G>A	p.Arg122Gln	2.9x10 ⁻⁶	0%	0%	0.19% (1)	0.58% (3)
B) Sufficiently rare variants (gnomAD FAF_{popmax} ≤ 0.00126) to cause biallelic HCM								
MYBPC3	Missense	c.3676C>T	p.Arg1226Cys	6.4x10 ⁻⁵	0%	0%	0.19% (1)	0%
	Missense	c.2618C>A	p.Pro873His	9.3x10 ⁻⁵	0%	0%	0.19% (1)	0%
	Missense	c.1321G>A	p.Glu441Lys	2.0x10 ⁻⁴	0%	2.0% (8)	0.39% (2)	4.3% (22)
MYL3	Missense	c.530A>G	p.Glu177Gly	4.4x10 ⁻⁵	0%	0.75% (3)	0.78% (4)	0.19% (1)
	Missense	c.170C>A	p.Ala57Asp	4.0x10 ⁻⁴	0%	0%	0.39% (2)	0.19% (1)
JPH2	Missense	c.572C>G	p.Pro191Arg [‡]	2.0x10 ⁻⁴	0%	0.25% (1)	0.19% (1)	0.19% (1)

A) Summary of Egyptian variants that are sufficiently rare (gnomAD FAF_{popmax} ≤ 4x10⁻⁵) to cause mono allelic disease. B) Additional variants that are sufficiently rare (gnomAD FAF_{popmax} ≤ 0.00126) to cause biallelic disease are also shown. *The MYH7 variant c.5769delG was caused by a nucleotide deletion that was predicted to ultimately give rise to a near full-length protein (i.e., only 4 AAs shorter than the wildtype). The control frequency represents heterozygous counts (no homozygous variants were identified). †This variant is unlikely to be pathogenic as it co-occurred with the pathogenic MYH7 variant p.Arg870His in the HCM patient (also, it's allele frequency in gnomAD-Ashkenazi Jewish population is 0.007215).

367

368

369

370

Table 4: Relative contribution of homozygous variants for validated autosomal dominant HCM genes

Gene/Gene groups	Variants with gnomAD $FAF_{popmax} \leq 4 \times 10^{-5}$		Additional variants with gnomAD $FAF_{popmax} \leq 0.00126$		Total hom freq (count/total)
	Total no. of patients	Hom case freq(count)	Total no. of patients	Hom case freq(count)	
<i>MYH7</i>	99	6.1% (6)	5	0%	5.8% (6/104)
<i>MYBPC3</i>	85	5.9% (5)	45	8.9% (4)	6.9% (9/130)
<i>CSRP3</i>	15	33.3% (5)	0	0%	33.3% (5/15)
<i>Myosin light chain</i>	28	14.3% (4)	11	54.5% (6)	25.6% (10/39)
<i>Thin filament</i>	18	5.6% (1)	8	0%	3.8% (1/26)
<i>ACTN2</i>	12	0%	8	0%	0% (0/20)
<i>JPH2</i>	14	0%	4	25% (1)	5.6% (1/18)
<i>PLN</i>	0	0%	0	0%	0%

371

372


373

374

375

For genes with an excess burden of rare variants in Egypt HCM patients vs. UK (Table 2). The relative contribution of rare (gnomAD $FAF_{popmax} \leq 4 \times 10^{-5}$) homozygous variants under dominant HCM model (left) as well as of additional variants under recessive inheritance model (gnomAD $FAF_{popmax} \leq 0.00126$) (right) are shown. MLC: *MYL2*, *MYL3*. Thin filament: *ACTC1*, *TNNC1*, *TNNI3*, *TNNT2*, *TPM1*.

376



377

378

379

380

Figure 2: Comparison of the rate of homozygosity across the analyzed dominant HCM genes. MLC- (*MYL2*, *MYL3*) and *CSRP3* genes showed a markedly higher rate of homozygosity compared to major HCM genes (*MYBPC3*, *MYH7*) and thin filament genes (*ACTC1*, *TNNC1*, *TNNI3*, *TNNT2*, *TPM1*).


381 **A significantly higher proportion of VUSs is observed in the Egypt HCM cohort**
382 **compared to UK HCM**

383 In contrast to MENA populations, European HCM patients have been extensively studied over
384 the past decades. As a result, they are more likely to carry a disease-causing variant that has
385 been previously well-characterized. Therefore, we hypothesize that in patients with rare
386 variants in validated HCM genes, Egyptians have a higher proportion of VUSs compared to
387 the UK HCM cohort.

388

389 The proportion of patients with rare variants in HCM genes was 46.7% (n=240) and 28.9%
390 (n=198) in the Egypt and UK HCM cohorts, respectively. As expected, the proportion of VUSs
391 was significantly higher in the Egypt HCM cohort compared to UK (59.2% vs. 38.4%, p-
392 value= 1.6×10^{-5}), which highlights the challenge in interpreting variants in understudied
393 populations (Figure 3).

394



395

396 **Figure 3: Higher proportion of Variants of Uncertain Significance (VUSs) is observed in (A)**
397 **Egyptian patients compared to (B) UK.** For patients with rare variants in validated HCM genes, the
398 distribution of rare variants by variant classification (pathogenic (P), Likely Pathogenic (LP) and VUSs)
399 is shown. For patients with multiple hits (Supplementary Tables 6 and 7) the variant with the highest
400 pathogenicity was prioritized (i.e., P then LP then VUS). The proportion of VUSs was significantly higher
401 in Egypt HCM patients vs. UK (59.2% vs. 38.4%, p-value= 1.6×10^{-5}).

402

403 **Analysis of HCM rare variation in the ancestry-matched Egyptian case-control cohort**
404 **increases the proportion of clinically actionable variants**

405 The availability of genetic data from a deeply-phenotyped control cohort of 400 Egyptians as
406 well as cohort-level analysis of the HCM patients described here enabled us to re-evaluate
407 the classification of identified VUSs in patients by adopting 3 approaches. First, we examined
408 whether these VUSs were prevalent among our control cohort (i.e. $n \geq 2$; $MAF \geq 0.0025$), which
409 would increase the likelihood of them being likely benign. Then, we assessed if a subset of
410 these VUSs could be reclassified to LP based on their enrichment in Egyptian patients
411 (ACMG/AMP PS4 rule) or whether they reside in a previously defined mutational hotspot
412 region that has been reported to be enriched for HCM-associated variation (modified
413 ACMG/AMP PM1 rule)^{13,32}.

414

415 Our analysis showed that 1 VUS (*MYBPC3* c.305C>T [p.Pro102Leu]) was observed in two
416 Egyptian controls and thus could be reclassified to likely benign according to the ACMG/AMP
417 rules BS1 and BP4²⁹. It is worth mentioning that here variant rarity was defined using
418 gnomAD, which lacks sufficient data from MENA populations. Given that variant frequencies
419 may differ across diverse ancestral populations, it is not unexpected to observe “rare” variants
420 in gnomAD to be more prevalent in Egypt (more details in Supplementary Figure 1).

421

422 We then adopted the modified ACMG/AMP PS4 rule proposed by ClinGen, whereby variants
423 prevalent among at least 2, 6 or 15 patients could activate the PS4- supporting, moderate and
424 strong rules, respectively³². The PS4 evidence strength levels associated with these specific
425 patient counts were based on likelihood ratios with ideal target thresholds set by ClinGen of
426 10 (PS4-supporting), 30 (moderate) and 100 (strong), respectively³². Of all rare variants
427 identified in Egypt HCM patients, irrespective of variant classification, 48,3 and 1 distinct
428 variant(s) were recurrently found in $n \geq 2$, $n \geq 6$ and $n \geq 15$ patients, respectively. Application

429 of the modified PS4 rule upgraded the classification of 6/104 VUSs to LP (5.8%) and 10/30
430 LP variants to P (33.3%).

431

432 We previously identified specific regions in sarcomeric genes in which rare non-truncating
433 variants were significantly enriched in >6,000 HCM patients of predominantly European-
434 ancestry (LMM/OMGL) compared to controls ²¹. For variants residing in these case-enriched
435 clusters, the etiological fraction (EF) was calculated as it provides a quantitative estimate of
436 the probability that a rare non-truncating variant identified in an individual with HCM is disease-
437 causing. Based on the EF findings, the authors proposed an adaptation to the ACMG/AMP
438 guidelines whereby rare variants located in an HCM cluster with an $EF \geq 0.95$ could activate
439 the PM1 hotspot rule at a modified strong evidence level (leading to the re-classification of
440 VUS to LP).


441

442 As the relative case-control frequencies can differ across population groups, similar
443 enrichment needs to be demonstrated in the population of interest before adopting these
444 modified guidelines. Given the abundance of rare non-truncating variants observed in *MYH7*
445 in the Egypt HCM cohort, we sought to validate the EF-based PM1 ACMG/AMP rule for *MYH7*
446 variants (there were insufficient variants to accurately assess clustering in the troponin genes).
447 First, we examined whether the distribution and enrichment of *MYH7* non-truncating variants
448 was similar between the Egypt and the LMM/OMGL (n=6,112) HCM datasets. As depicted in
449 Figure 4A, a similar distribution of rare missense *MYH7* variants was observed between
450 Egyptian and LMM/OMGL HCM patients, with rare variants in the pre-defined HCM cluster
451 (residues 167-931) significantly enriched in the Egypt HCM cohort over Egypt controls
452 (13.04% vs. 0.25%, p-value=2.2x10⁻¹⁶). As the EF for Egyptian variants within the pre-defined
453 HCM cluster was 1.0 (95%CI: 0.93-1.0), we applied the EF-based PM1_strong ACMG/AMP
454 on rare Egyptian *MYH7* missense variants, irrespective of prior variant classification. A total
455 of 48 missense *MYH7* variants were identified in the Egypt HCM cohort (Supplementary Table
456 2). Application of the EF-based PM1_strong rule upgraded the classification of 23 VUSs to LP

457 and three LP variants to P, which increased the overall proportion of clinically actionable (i.e.
458 P/LP) distinct *MYH7* missense variants from 35.4% to 83.3%.

459
460 Taken together, applying the above-mentioned approaches to variant interpretation increased
461 the overall proportion of Egypt HCM patients with clinically actionable variants from 19% to
462 33.4% (relative increase from 40.8% to 60.4% in the patient subgroup with rare variants in
463 validated HCM genes) (Figure 4B).

464
465



466
467 **Figure 4: A) Similar enrichment of rare, missense *MYH7* variants between the Egypt- and large-**
468 **scale HCM cohort of predominantly European ancestry (LMM/OMGL n=6,112) in the predefined**
469 **HCM cluster (red) (residues 167-931). Rare variants in the HCM cluster were enriched in the Egypt**
470 **HCM cohort over Egypt controls with an Etiological Fraction (EF) of 1.0. B) Application of ClinGen's**
471 **modified ACMG/AMP PS4 rule and Walsh et al., 2019 proposed EF-based PM1 strong rules in**
472 **the Egyptian case-control cohort increases the proportion of Egypt HCM patients with clinically**
473 **actionable variants from 19% to 33.4%. Rare variants were initially classified based on the**
474 **ACMG/AMP guidelines (initial analysis) and then reclassified after integrating ancestry-matched**
475 **controls into the analysis (cohort-informed analysis) and adopting Egypt-specific PS4 and the modified**
476 **EF-based PM1 strong rules. Cohort-informed analysis revealed that *MYBPC3* p.Pro102Leu was**
477 **prevalent in the Egypt control cohort (MAF=0.0025) and thus was reclassified from VUS (in case-level**
478 **analysis) to likely benign (LB, activated ACMG/AMP rules: BS1&BP4). P: pathogenic, LP: likely**
479 **pathogenic, VUS: variant of uncertain significance.**

480
481

482 **Enrichment of non-rare variants in Egypt HCM patients**

483 A growing body of evidence suggests that low frequency variants could contribute to disease
484 risk with intermediate effects³³. These variants can be identified through burden tests showing
485 an enrichment in patients followed by functional analyses to investigate their effect on the
486 disease phenotype. Therefore, we sought to assess if low-frequency variants (i.e. $4 \times 10^{-5} <$
487 $\text{gnomAD FAF}_{\text{popmax}} < 0.01$) were enriched in the Egypt HCM cohort compared to Egypt
488 controls. A total of 20 non-rare protein-altering variants in validated HCM genes were
489 observed in more than one patient in the Egypt HCM cohort (Supplementary Table 10). Of
490 these, *MYBPC3* c.1321G>A [p.Glu441Lys] and *TNNT2* c.832C>T [p.Arg278Cys] were
491 nominally enriched in Egyptian patients over controls (4.67% vs. 2%, p-value=0.03, OR=2.4
492 (95%CI: 1.0-6.2) and 1.17% vs. 0%, p-value=0.04, OR=10.2 (95%CI: 0.6-182.3), respectively)
493 (although not statistically significant after multiple testing correction). While p.Arg278Cys is
494 enriched in HCM in both Egyptian and European-ancestry cohorts, including the analyzed UK
495 cohort, p.Glu441Lys is infrequently observed in most European HCM cohorts (Supplementary
496 Table 11)³⁴⁻³⁷. This suggests that this variant could be more relevant to Middle Eastern
497 populations. Several publications reported the frequent co-occurrence of these variants with
498 other sarcomeric variants suggesting that they may act as disease modifiers^{33,38-41}. Notably,
499 37.5% (n=9/24) and 33.3% (n=2) of Egyptian patients with p.Glu441Lys and p.Arg278Cys,
500 respectively, carried another rare sarcomeric variant, including two patients who carried
501 p.Glu441Lys in homozygosity (Supplementary Table 11).

502

503 **Higher prevalence of *TRIM63* biallelic variants in the Egypt HCM cohort compared to** 504 **Europeans**

505 Salazar-Mendiguchía *et al.*, 2020 have recently proposed that *TRIM63* is a recessive HCM
506 gene associated with concentric LVH and a high rate of LV dysfunction following the
507 identification of homozygous or compound heterozygous variants in 0.4% of a predominantly
508 European (>90%) HCM cohort⁴². We identified seven homozygous and one compound
509 heterozygous *TRIM63* variants in the Egypt HCM cohort (total=8/374, 2.14%) (Supplementary

510 Table 9). No biallelic *TRIM63* variants were identified in the Egypt control cohort. Similar to
511 the recent study, c.224G>A [p.Cys75Tyr] (1.34%) and c.739C>T [p.Gln247Ter] (0.53%) (both
512 homozygous) were the most frequently identified *TRIM63* biallelic variants in the Egypt HCM
513 cohort⁴². The missense variant Cys75Tyr was observed in heterozygosity in 0.5% (2/400) of
514 the Egypt control cohort and in two individuals from the North African sub-populations from
515 the GME study (in hetero- and homozygosity), which indicates that this variant could be
516 particularly prevalent in North African/MENA populations⁴³. A markedly higher frequency of
517 biallelic *TRIM63* variants was observed in the Egypt HCM cohort compared to both the
518 analyzed UK HCM cohort and the recently published European-ancestry enriched cohort
519 (2.14%% vs 0.16%, p-value=0.0019 and vs. 0.4%, p-value=5.8x10⁻⁵, respectively)⁴².

520

521 Discussion

522 This study represents the largest and most comprehensive analysis of HCM in the MENA
523 region to date. Here, we report the results of genetic analysis of 514 unrelated Egyptian HCM
524 patients and 400 ancestry-matched controls. We show that cohort-level analysis of rare
525 variation in the hitherto understudied Egyptian population provides accurate interpretation of
526 variants rarely observed in published HCM patient groups. In addition, we demonstrate that
527 studying consanguineous populations allows for distinguishing between the relative
528 pathogenicity and penetrance of disease-causing genes.

529

530 First, we show that the proportion of patients with rare variants in validated HCM genes was
531 higher in the Egypt HCM cohort compared to UK HCM (52.7% vs. 32.0%). Recent data from
532 ShaRe registry demonstrated that patients carrying sarcomere variants presented with HCM
533 at an earlier age and had a worse prognosis¹⁰. Here, Egyptian patients presented with a
534 higher yield of sarcomeric variants compared to the UK HCM cohort (44.8% vs. 29.5%).

535

536 Patients analyzed here were admitted to AHC, which is a tertiary referral center. Thus, they
537 typically presented with severe clinical manifestations at admission. This may explain the
538 markedly younger age of onset (by ca. 20 years) and more severe LVH observed in the Egypt
539 HCM cohort compared to UK HCM. To account for a possible referral bias, we compared the
540 proportion of genotype positive patients attributable to each gene between the Egypt and UK
541 HCM cohorts.

542

543 *MYBPC3* and *MYH7* accounted for the majority of rare variation, as with all HCM cohorts.
544 However, some key differences are observed between the Egypt HCM and UK HCM cohorts.
545 For example, we have recently reported the identification of a new class of pathogenic variants
546 in HCM; a nonsense mediated decay-incompetent frameshift variant (c.5769delG) in *MYH7*,
547 which was recurrently observed in Egyptian patients (3.3%) and absent from large-scale
548 ($n > 6,000$) HCM patients of predominantly European ancestry^{16,18}. Also, the Egypt HCM data
549 shows an enrichment of *JPH2* missense variants (5.2% Egypt HCM vs. 1.4% UK HCM
550 genotype-positive patients) which rarely cause HCM outside of founder populations. This is
551 largely explained by two recurrent variants that have not been previously reported²⁵. One of
552 these variants, p.Thr161Ala, occurs at the same position as another pathogenic variant
553 (p.Thr161Lys) recently reported to be a founder in the Finnish population⁴⁴. This may denote
554 a particular pathogenic hotspot in *JPH2* although further segregation and/or functional data
555 are required to enable a more accurate classification of these variants.

556

557 The main unique finding, however, relates to the clear prevalence of HCM minor genes,
558 particularly *MYL2*, *MYL3* (MLC) and *CSRP3*, in the Egyptian population and the enrichment
559 of homozygous variants in these genes. A noticeably higher proportion of rare variants in MLC
560 genes was observed in the genotype-positive Egypt HCM cohort compared to UK HCM
561 (10.33% vs. 2.28%), including five recurrent variants that were absent from the latter cohort.
562 Interestingly, a substantial proportion of MLC variants (25.6%) were observed in the
563 homozygous state, suggesting such variants are less penetrant in heterozygosity. In

564 agreement with this notion, a study by Claes *et al.*, 2016 demonstrated that the expression of
565 the Dutch founder *MYL2* missense variant p.Glu22Lys in isolation was associated with low
566 HCM penetrance and a benign disease manifestation and that the presence of an additional
567 risk factor, including hypertension, obesity or the co-occurrence of another sarcomeric variant,
568 increased the disease penetrance from 36% to 89% in *MYL2*-variant carriers⁴⁵. In addition,
569 the authors reported that patients carrying p.Glu22Lys in homozygosity were diagnosed with
570 end-stage heart failure due to HCM in their 30s⁴⁵. It is therefore plausible to conclude that the
571 high consanguinity rates observed in the Egypt HCM cohort enabled MLC variants to occur in
572 a more penetrant homozygous state. This may explain, at least in part, the relatively higher
573 proportion of rare MLC variants observed in the analyzed consanguineous Egypt HCM cohort
574 compared to UK HCM. While biallelic truncating variants in *MYL2/MYL3* are associated with
575 severe early onset cardioskeletal myopathies, only two homozygous missense variants
576 in *MYL3* have previously been reported - p.Glu143Lys^{46,47} and p.Ala57Asp^{48,49}. It is
577 noteworthy that the homozygous expression of the non-rare variant p.Ala57Asp, which was
578 observed in HCM patients of Iranian and Tunisian origins born to consanguineous parents^{48,49},
579 was also observed in the Egypt HCM cohort (in two homozygous and one heterozygous
580 carriers). The homozygous patients presented with HCM at a relatively younger age and had
581 a greater LVWMT (27+2.8mm vs. 16mm) compared to the heterozygous carrier. Although a
582 previous functional study with iPSC-CMs did not demonstrate a phenotype for this variant in
583 either the heterozygous or homozygous state⁵⁰, the fact that it has now been detected as a
584 homozygous variant in four HCM cases (and not detected in our healthy control cohort)
585 suggests it is contributing to the phenotype.

586
587 Similar to MLC-encoding genes, variants in *CSRP3* were more likely to present in
588 homozygosity (33.3%) than the major sarcomere-encoding HCM genes (*MYH7*, *MYBPC3* and
589 thin filament genes, 5-7%). Two of the three homozygous *CSRP3* variants were truncating
590 (c.415-1G>C and c.414+1G>T). These variants were observed in one and three Egyptian
591 patients, respectively. Patients carrying these variants presented with HCM at an average age

592 of 45.5±8.7 and a LVMWT of 16.5±2.4mm. It is noteworthy that c.414+1G>T was also
593 observed in heterozygosity in one Egyptian control and HCM patient, respectively. The control
594 did not carry any other rare HCM-associated variant whereas the HCM patient carried the
595 pathogenic *MYH7* c.5769delG variant (and the *JPH2* p.Ser99Asn VUS), suggesting that in the
596 heterozygous state this variant requires an additional mutational burden to express the HCM
597 phenotype. To date, only three knockout *CSRP3* HCM patients have been reported in Poland
598 and France, two of whom were confirmed to be born to consanguineous parents^{51,52}. These
599 patients were diagnosed with adult-onset HCM and one patient underwent Implantable
600 cardioverter defibrillator implantation in her 30s^{51,52}. Together, these studies suggest that full
601 *CSRP3* gene knockouts, in contrast to the severe early-onset phenotypes observed with
602 biallelic truncating variants in genes like *MYBPC3* and *ALPK3*, are associated with more
603 typical adult-onset HCM, despite the fact that most reports for *CSRP3*-associated HCM
604 involve heterozygous variants and dominant inheritance.

605

606 Taken together, these findings demonstrate that this study is uniquely able to examine the
607 frequency of homozygous variants in dominant HCM genes using a large consanguineous
608 cohort to inform the relative penetrance of variants in these genes. The recurrence of these
609 variants in the Egyptian cohort, which may indeed have generally higher prevalence in other
610 consanguineous populations of the MENA region, exemplifies the need to integrate new
611 guidelines tailored to the classification of homozygous variants into the current ACMG
612 framework in order to enhance the utility of clinical genetic testing in other consanguineous
613 populations.

614

615 The observed high prevalence of consanguinity (28%) in the Egyptian cohort analyzed here
616 has also enabled us to validate recent findings reporting the association of the recessive gene
617 *TRIM63* to HCM⁴². Indeed, the prevalence of biallelic *TRIM63* variants was markedly higher
618 in Egyptian patients compared to HCM patients of European ancestries suggesting that

619 recessive inheritance patterns of HCM are more likely to occur in consanguineous populations
620 of the MENA region.

621
622 Our data also highlight the value of performing ancestry-matched case-control analysis
623 coupled with standardized guidelines and quantitative approaches to variant interpretation to
624 accurately classify variants observed in underrepresented populations^{13,29,32}. We demonstrate
625 that these approaches enabled 23.1% of distinct VUSs identified in the Egypt HCM cohort to
626 progress to likely pathogenic, enabling a more equitable application of clinical genetic testing
627 in the region. Expanding the MENA dataset in resources like gnomAD will further improve the
628 interpretation of VUSs by providing more accurate frequencies of these variants in the
629 population.

630
631 It is noteworthy that despite the relatively severe phenotypes observed in our cohort, almost
632 50% of HCM patients in this study presented with an unexplained genetic etiology. This finding
633 is not unexpected as recent evidence suggests that the genetic etiology of HCM is more
634 complex and that common variants with individually small (but collectively large) effect sizes
635 could explain some of the missing heritability of the disease^{53,54}. This study is not designed
636 to assess common variants or validate recently described European-ancestry HCM polygenic
637 risk scores (PRS)⁵⁴. However, a recent HCM genome-wide association study (GWAS)
638 identified a common *BAG3* missense variant p.Cys151Arg, as one of the two most strongly
639 associated loci for HCM and which is covered by the targeted gene panel used in this
640 analysis⁵⁴. The OR of p.Cys151Arg was highly similar between the Egyptian cohorts and the
641 published European datasets, 1.47 (95%CI: 1.12-1.95) and 1.42 (95%CI: 1.29-1.55)
642 respectively⁵⁴, although the population frequency for the minor risk allele is lower in Egypt
643 (control MAF=0.12) than Europe (gnomAD-non-Finnish European MAF=0.22). This suggests
644 that there will be likely many shared loci between populations, although well-powered GWAS
645 in MENA populations are warranted to accurately quantify HCM PRS for future clinical use.
646

647 Low frequency variants with effect sizes that are intermediate between common GWAS-
648 derived and rare Mendelian variants are now also emerging as additional genetic risk factors.
649 For example, a recent study by Pua *et al.* identified two low frequency troponin variants (*TNNI3*
650 p.Arg79Cys OR=3.3 (96%CI: 1.5-7.2), MAF=0.018 and *TNNT2* p.Arg286His OR=14.1
651 (95%CI: 6.0-33.0), MAF=0.022) that are associated with HCM in patients of Chinese ancestry
652 ⁵⁵. Similarly, we observed two low frequency variants *MYBPC3* p.Glu441Lys (OR=2.4 (95%CI:
653 1.0-6.2), MAF=0.025) and *TNNT2* p.Arg278Cys (OR= 10.2 (95%CI: 0.6-182.3), MAF=0.006)
654 that were nominally enriched in the Egyptian HCM cohort. While the *TNNT2* p.Arg278Cys
655 variant is also consistently enriched in European ancestry cohorts, the *MYBPC3* variant
656 p.Glu441Lys is clearly more prevalent in the Egypt HCM cohort, suggesting that it could be
657 more relevant to Egyptian patients ³⁴⁻³⁷. In agreement with literature findings, both variants
658 were frequently observed in conjunction with another sarcomeric variant in Egyptian patients,
659 which suggests their modifier effect on the phenotype ³⁸⁻⁴¹. However, functional studies will
660 be required to definitively ascertain their effect on HCM phenotype.

661

662 A limitation of the study is that the targeted gene panel used does not include genes that have
663 been recently shown to be associated with HCM (*ALPK3*, *FHOD3* and *FLNC* ⁵⁶⁻⁵⁹). In addition,
664 the study design did not account for common and copy number variations, non-coding variants
665 or epigenetic factors, which may contribute to HCM pathogenesis. Finally, larger control
666 datasets are needed to fully characterize rare variation in MENA populations.

667

668 In conclusion, we have demonstrated that detailed analysis of rare genetic variation in
669 validated HCM genes in underrepresented populations reveals novel findings with relevance
670 to both clinical genetic testing and our understanding of the genetic etiology of HCM. We report
671 the contribution of minor HCM genes, rarely observed in outbred populations, to disease
672 pathogenicity. We also show a higher prevalence of biallelic variants in the recessive HCM
673 gene *TRIM63* in Egyptian patients suggesting that recessive inheritance of HCM is more likely
674 to occur in consanguineous populations. These unique genetic features exemplify the value

675 of studying diverse ancestral populations. The highly consanguineous cohort analyzed here
676 opens new research avenues for the discovery of novel recessive genes in future exome or
677 genome sequencing studies.

678

679 **Acknowledgements**

680 We would like to acknowledge Dr. Rafik Tadros and Dr. Paloma Jordà for providing us with
681 HCM and control frequency data regarding the recently reported *BAG3* variant p.Cys151Arg.
682 We would like to thank the AHC nursing staff and team members who contributed to the
683 biobanking efforts in frame of the National HCM Registry.

684

685 **Funding Statement**

686 This study is part of the Egyptian Collaborative Cardiac Genomics Project. It was supported
687 by the Science and Technology Development Fund government grant (Egypt), the Wellcome
688 Trust (107469/Z/15/Z; 200990/A/16/Z), the Medical Research Council (United Kingdom), the
689 NIHR Royal Brompton Cardiovascular Biomedical Research Unit, the NIHR Imperial College
690 Biomedical Research Center, and a Health Innovation Challenge Fund award from the
691 Wellcome Trust* and Department of Health, United Kingdom (HICF-R6–373)**. Drs Allouba
692 and Halawa were funded by Al Alfi Foundation to support their PhD degrees at Imperial
693 College London and American University in Cairo, respectively. Dr Aguib is supported by
694 Fondation Leducq (11 CVD-01).

695 *This research was funded in part by the Wellcome Trust [107469/Z/15/Z]. For the purpose of
696 open access, the author has applied a CC BY public copyright licence to any Author Accepted
697 Manuscript version arising from this submission.

698 **The views expressed in this work are those of the authors and not necessarily those of the
699 funders.

700

701

702 **Web resources**

703 OMIM, <https://www.omim.org>

704

705

706 **References**

- 707 1. Maron, B. J., Gardin, J. M., Flack, J. M., Gidding, S. S., Kurosaki, T. T., & Bild, D. E.
708 (1995). Prevalence of hypertrophic cardiomyopathy in a general population of young
709 adults: Echocardiographic analysis of 4111 subjects in the CARDIA study. *Circulation*,
710 92(4), 785–789. <https://doi.org/10.1161/01.CIR.92.4.785>
- 711 2. Semsarian, C., Ingles, J., Maron, M. S., & Maron, B. J. (2015). New perspectives on
712 the prevalence of hypertrophic cardiomyopathy. In *Journal of the American College of*
713 *Cardiology* (Vol. 65, Issue 12). <https://doi.org/10.1016/j.jacc.2015.01.019>
- 714 3. Teare, D. (1958). Asymmetrical hypertrophy of the heart. *British Heart Journal*, 20(1),
715 1–8.
- 716 4. Maron, M. S., & Maron, B. J. (2015). Clinical impact of contemporary cardiovascular
717 magnetic resonance imaging in hypertrophic cardiomyopathy. *Circulation*, 132(4).
718 <https://doi.org/10.1161/CIRCULATIONAHA.114.014283>
- 719 5. Maron, B. J., Ommen, S. R., Semsarian, C., Spirito, P., Olivetto, I., & Maron, M. S.
720 (2014). Hypertrophic cardiomyopathy: Present and future, with translation into
721 contemporary cardiovascular medicine. In *Journal of the American College of*
722 *Cardiology* (Vol. 64, Issue 1). <https://doi.org/10.1016/j.jacc.2014.05.003>
- 723 6. Maron, B. J., Rowin, E. J., Casey, S. A., & Maron, M. S. (2016). How Hypertrophic
724 Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low
725 Mortality. *JAMA Cardiology*, 1(1). <https://doi.org/10.1001/jamacardio.2015.0354>
- 726 7. Marian, A. J., & Braunwald, E. (2017). Hypertrophic cardiomyopathy: Genetics,
727 pathogenesis, clinical manifestations, diagnosis, and therapy. *Circulation Research*,
728 121(7), 749–770. <https://doi.org/10.1161/CIRCRESAHA.117.311059>
- 729 8. Lu, D. Y., Pozios, I., Haileselassie, B., Ventoulis, I., Liu, H., Sorensen, L. L., Canepa,
730 M., Phillip, S., Roselle Abraham, M., & Abraham, T. P. (2018). Clinical outcomes in
731 patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy.
732 *Journal of the American Heart Association*, 7(5).
733 <https://doi.org/10.1161/JAHA.117.006657>
- 734 9. O'Mahony, C., Jichi, F., Ommen, S. R., Christiaans, I., Arbustini, E., Garcia-Pavia, P.,
735 Cecchi, F., Olivetto, I., Kitaoka, H., Gotsman, I., et al. (2018). International external
736 validation study of the 2014 European society of cardiology guidelines on sudden
737 cardiac death prevention in hypertrophic cardiomyopathy (EVIDENCE-HCM).
738 *Circulation*, 137(10). <https://doi.org/10.1161/CIRCULATIONAHA.117.030437>
- 739 10. Ho, C. Y., Day, S. M., Ashley, E. A., Michels, M., Pereira, A. C., Jacoby, D., Cirino, A.
740 L., Fox, J. C., Lakdawala, N. K., Ware, J. S., et al. (2018). Genotype and Lifetime
741 Burden of Disease in Hypertrophic Cardiomyopathy. *Circulation*, 138(14), 1387–1398.
742 <https://doi.org/10.1161/CIRCULATIONAHA.117.033200>
- 743 11. Elliott, P. (2018). Hypertrophic cardiomyopathy lifelong disease requiring lifelong
744 treatment. In *Circulation* (Vol. 138, Issue 14).
745 <https://doi.org/10.1161/CIRCULATIONAHA.118.035932>
- 746 12. Olivetto, I., Oreziak, A., Barriales-Villa, R., Abraham, T. P., Masri, A., Garcia-Pavia, P.,
747 Saberi, S., Lakdawala, N. K., Wheeler, M. T., Owens, A., et al. (2020). Mavacamten
748 for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-
749 HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet*,
750 396(10253). [https://doi.org/10.1016/S0140-6736\(20\)31792-X](https://doi.org/10.1016/S0140-6736(20)31792-X)
- 751 13. Walsh, R., Mazzarotto, F., Whiffin, N., Buchan, R., Midwinter, W., Wilk, A., Li, N.,
752 Felkin, L., Ingold, N., Govind, R., et al. (2019). Quantitative approaches to variant

- 753 classification increase the yield and precision of genetic testing in Mendelian diseases :
754 the case of hypertrophic cardiomyopathy. *Genome Medicine*, 11(5), 1–18.
- 755 14. Dellefave-Castillo, L. M., Cirino, A. L., Callis, T. E., Esplin, E. D., Garcia, J., Hatchell,
756 K. E., Johnson, B., Morales, A., Regalado, E., Rojahn, S., et al. (2022). Assessment
757 of the Diagnostic Yield of Combined Cardiomyopathy and Arrhythmia Genetic Testing.
758 *JAMA Cardiology*. <https://doi.org/10.1001/jamacardio.2022.2455>
759
- 760 15. Landry, L. G., & Rehm, H. L. (2018). Association of racial/ethnic categories with the
761 ability of genetic tests to detect a cause of cardiomyopathy. *JAMA Cardiology*, 3(4),
762 341–345. <https://doi.org/10.1001/jamacardio.2017.5333>
- 763 16. Aguib, Y., Allouba, M., Walsh, R., Ibrahim, A. M., Halawa, S., Afify, A., Hosny, M.,
764 Theotokis, P. I., Galal, A., Elshorbagy, S., et al. (2021). New Variant with a Previously
765 Unrecognized Mechanism of Pathogenicity in Hypertrophic Cardiomyopathy.
766 *Circulation*, 144(9), 754–757. <https://doi.org/10.1161/CIRCULATIONAHA.120.048295>
- 767 17. Aguib, Y., Allouba, M., Afify, A., Halawa, S., El-Khatib, M., Sous, M., Galal, A.,
768 Abdelrahman, E., Shehata, N., el Sawy, et al. (2020). The Egyptian Collaborative
769 Cardiac Genomics (ECCO-GEN) Project: defining a healthy volunteer cohort. *Npj*
770 *Genomic Medicine*, 5(46). <https://doi.org/10.1038/s41525-020-00153-w>
- 771 18. Walsh, R., Thomson, K. L., Ware, J. S., Funke, B. H., Woodley, J., McGuire, K. J.,
772 Mazarotto, F., Blair, E., Seller, A., Taylor, J. C., et al. (2017). Reassessment of
773 Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706
774 reference samples. *Genetics in Medicine*, 19(2), 192–203.
775 <https://doi.org/10.1038/gim.2016.90>
- 776 19. Shawky, R. M., El-Awady, M. Y., Elsayed, .Solaf M., & Hamadan, G. E. (2011).
777 Consanguineous matings among Egyptian population. *The Egyptian Journal of*
778 *Medical Human Genetics*, 12, 157–163. <https://doi.org/10.1016/j.ejmhg.2011.07.001>
- 779 20. Shawky, R. M., Elsayed, N. S., Ibrahim, D. S., & Seifeldin, N. S. (2012). Profile of
780 genetic disorders prevalent in northeast region of Cairo, Egypt. *Egyptian Journal of*
781 *Medical Human Genetics*, 13(1), 45–62. <https://doi.org/10.1016/j.ejmhg.2011.10.002>
- 782 21. Walsh, R., Buchan, R., Wilk, A., John, S., Felkin, L. E., Thomson, K. L., Chiaw, T. H.,
783 Chin, C., Loong, W., Pua, C. J., et al. (2017). Defining the genetic architecture of
784 hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes.
785 *European Society of Cardiology*, 38, 3461–3468.
786 <https://doi.org/10.1093/eurheartj/ehw603>
- 787 22. de Marvao, A., Dawes, T. J. W., Shi, W., Durighel, G., Rueckert, D., Cook, S. A., &
788 O'Regan, D. P. (2015). Precursors of hypertensive heart phenotype develop in healthy
789 adults A High-Resolution 3D MRI Study. *JACC: Cardiovascular Imaging*.
790 <https://doi.org/10.1016/j.jcmg.2015.08.007>
- 791 23. Pua, C. J., Bhalshankar, J., Miao, K., Walsh, R., John, S., Lim, S. Q., Chow, K.,
792 Buchan, R., Soh, B. Y., Lio, P. M., et al. (2016). Development of a Comprehensive
793 Sequencing Assay for Inherited Cardiac Condition Genes. *Journal of Cardiovascular*
794 *Translational Research*, 9(1), 3–11. <https://doi.org/10.1007/s12265-016-9673-5>
- 795 24. Ingles, J., Goldstein, J., Thaxton, C., Caleshu, C., Corty, E. W., Crowley, S. B.,
796 Dougherty, K., Harrison, S. M., McGlaughon, J., Milko, L. v., et al. (2019). Evaluating
797 the Clinical Validity of Hypertrophic Cardiomyopathy Genes. *Circulation: Genomic and*
798 *Precision Medicine*, 12(2), 57–64. <https://doi.org/10.1161/CIRCGEN.119.002460>
- 799 25. Walsh, R., Offerhaus, J. A., Tadros, R., & Bezzina, C. R. (2021). Minor hypertrophic
800 cardiomyopathy genes, major insights into the genetics of cardiomyopathies. *Nature*
801 *Reviews Cardiology*, 1–17. <https://doi.org/10.1038/s41569-021-00608-2>
- 802 26. Maron, B. J., Maron, M. S., & Semsarian, C. (2012). Genetics of hypertrophic
803 cardiomyopathy after 20 years: Clinical perspectives. In *Journal of the American*
804 *College of Cardiology* (Vol. 60, Issue 8, pp. 705–715).
805 <https://doi.org/10.1016/j.jacc.2012.02.068>
- 806 27. Whiffin, N., Minikel, E., Walsh, R., O'Donnell-Luria, A. H., Karczewski, K., Ing, A. Y.,
807 Barton, P. J. R., Funke, B., Cook, S. A., MacArthur, D., et al. (2017). Using high-

- 808 resolution variant frequencies to empower clinical genome interpretation. *Genetics in*
809 *Medicine*, 19(10), 1151–1158. <http://dx.doi.org/10.1038/gim.2017.26>
- 810 28. Whiffin, N., Walsh, R., Govind, R., Edwards, M., Ahmad, M., Zhang, X., Tayal, U.,
811 Buchan, R., Midwinter, W., Wilk, A. E., et al. (2018). CardioClassifier: disease- and
812 gene-specific computational decision support for clinical genome interpretation.
813 *Genetics in Medicine*, 20(10), 1246–1254. <https://doi.org/10.1038/gim.2017.258>
- 814 29. Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W.,
815 Hegde, M., Lyon, E., Spector, E., et al. (2015). Standards and guidelines for the
816 interpretation of sequence variants: a joint consensus recommendation of the
817 American College of Medical Genetics and Genomics and the Association for
818 Molecular Pathology. *Genetics in Medicine*, 17(5), 405–423.
819 <https://doi.org/10.1038/gim.2015.30>
- 820 30. Carrier, L., Mearini, G., Stathopoulou, K., & Cuello, F. (2015). Cardiac myosin-binding
821 protein C (MYBPC3) in cardiac pathophysiology. In *Gene* (Vol. 573, Issue 2, pp. 188–
822 197). <https://doi.org/10.1016/j.gene.2015.09.008>
- 823 31. Carrier, L. (2021). Targeting the population for gene therapy with MYBPC3. *Journal of*
824 *Molecular and Cellular Cardiology*, 150(September 2020), 101–108.
825 <https://doi.org/10.1016/j.yjmcc.2020.10.003>
- 826 32. Kelly, M. A., Caleshu, C., Morales, A., Buchan, J., Wolf, Z., Harrison, S. M., Cook, S.,
827 Dillon, M. W., Garcia, J., Haverfield, E., et al. (2018). Adaptation and validation of the
828 ACMG / AMP variant classification framework for MYH7 -associated inherited
829 cardiomyopathies : recommendations by ClinGen ' s Inherited Cardiomyopathy Expert
830 Panel. *Genetics in Medicine : Official Journal of the American College of Medical*
831 *Genetics*, 20(3), 351–359. <https://doi.org/10.1038/gim.2017.218>
- 832 33. Walsh, R., Tadros, R., & Bezzina, C. R. (2020). When genetic burden reaches
833 threshold. *European Heart Journal*, 41(39). <https://doi.org/10.1093/eurheartj/ehaa269>
- 834 34. Mazzarotto, F., Girolami, F., Boschi, B., Barlocco, F., Tomberli, A., Baldini, K., Coppini,
835 R., Tanini, I., Bardi, S., Contini, E., et al. (2019). Defining the diagnostic effectiveness
836 of genes for inclusion in panels: the experience of two decades of genetic testing for
837 hypertrophic cardiomyopathy at a single center. *Genetics in Medicine*, 21(2).
838 <https://doi.org/10.1038/s41436-018-0046-0>
- 839 35. Janin, A., Januel, L., Cazeneuve, C., Delinière, A., Chevalier, P., & Millat, G. (2021).
840 Molecular Diagnosis of Inherited Cardiac Diseases in the Era of Next-Generation
841 Sequencing: A Single Center's Experience Over 5 Years. *Molecular Diagnosis and*
842 *Therapy*, 25(3). <https://doi.org/10.1007/s40291-021-00530-w>
- 843 36. Alfares, A. A., Kelly, M. A., McDermott, G., Funke, B. H., Lebo, M. S., Baxter, S. B.,
844 Shen, J., McLaughlin, H. M., Clark, E. H., Babb, L. J., et al. (2015). Results of clinical
845 genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels
846 offer limited additional sensitivity. *Genetics in Medicine : Official Journal of the*
847 *American College of Medical Genetics*, 17(11), 880–888.
848 <https://doi.org/10.1038/gim.2014.205>
- 849 37. Lopes, L. R., Rahman, M. S., & Elliott, P. M. (2013). A systematic review and meta-
850 analysis of genotype-phenotype associations in patients with hypertrophic
851 cardiomyopathy caused by sarcomeric protein mutations. *Heart*, 99(24), 1800–1811.
852 <https://doi.org/10.1136/heartjnl-2013-303939>
- 853 38. Olivotto, I., Girolami, F., Ackerman, M. J., Nistri, S., Bos, J. M., Zachara, E., Ommen,
854 S. R., Theis, J. L., Vaubel, R. A., Re, F., et al. (2008). Myofilament protein gene
855 mutation screening and outcome of patients with hypertrophic cardiomyopathy. *Mayo*
856 *Clinic Proceedings*, 83(6), 630–638. <https://doi.org/10.4065/83.6.630>
- 857 39. Millat, G., Bouvagnet, P., Chevalier, P., Dauphin, C., Simon Jouk, P., da Costa, A.,
858 Prieur, F., Bresson, J. L., Faivre, L., Eicher, J. C., et al. (2010). Prevalence and
859 spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic
860 cardiomyopathy. *European Journal of Medical Genetics*, 53(5), 261–267.
861 <https://doi.org/10.1016/j.ejmg.2010.07.007>

- 862 40. Ripoll-Vera, T., Gámez, J. M., Govea, N., Gómez, Y., Núñez, J., Socías, L., Escandell,
863 Á., & Rosell, J. (2016). Clinical and Prognostic Profiles of Cardiomyopathies Caused
864 by Mutations in the Troponin T Gene. *Revista Española de Cardiología (English*
865 *Edition)*, 69(2). <https://doi.org/10.1016/j.rec.2015.06.025>
- 866 41. Gimeno, J. R., Monserrat, L., Pérez-Sánchez, I., Marín, F., Caballero, L., Hermida-
867 Prieto, M., Castro, A., & Valdés, M. (2009). Hypertrophic Cardiomyopathy. A Study of
868 the Troponin-T Gene in 127 Spanish Families. *Revista Española de Cardiología*
869 *(English Edition)*, 62(12). [https://doi.org/10.1016/s1885-5857\(09\)73545-5](https://doi.org/10.1016/s1885-5857(09)73545-5)
- 870 42. Salazar-Mendiguchiá, J., Ochoa, J. P., Palomino-Doza, J., Domínguez, F., Diéz-
871 López, C., Akhtar, M., Ramiro-León, S., Clemente, M. M., Pérez-Cejas, A., Robledo,
872 M., et al. (2020). Mutations in TRIM63 cause an autosomal-recessive form of
873 hypertrophic cardiomyopathy. *Heart*, 106(17). [https://doi.org/10.1136/heartjnl-2020-](https://doi.org/10.1136/heartjnl-2020-316913)
874 316913
- 875 43. Scott, E. M., Halees, A., Itan, Y., Spencer, E. G., He, Y., Azab, M. A., Gabriel, S. B.,
876 Belkadi, A., Boisson, B., Abel, L., et al. (2016). Characterization of Greater Middle
877 Eastern genetic variation for enhanced disease gene discovery. *Nature Genetics*,
878 48(9), 1071–1076. <https://doi.org/10.1038/ng.3592>
- 879 44. Vanninen, S. U. M., Leivo, K., Seppälä, E. H., Aalto-Setälä, K., Pitkänen, O.,
880 Suursalmi, P., Annala, A. P., Anttila, I., Alastalo, T. P., Myllykangas, S., et al. (2018).
881 Heterozygous junctophilin-2 (JPH2) p. (Thr161Lys) is a monogenic cause for HCM
882 with heart failure. *PLoS ONE*, 13(9). <https://doi.org/10.1371/journal.pone.0203422>
- 883 45. Claes, G. R. F., van Tienen, F. H. J., Lindsey, P., Krapels, I. P. C., Helderma-Van
884 Den Enden, A. T. J. M., Hoos, M. B., Barrois, Y. E. G., Janssen, J. W. H., Paulussen,
885 A. D. C., Sels, J. W. E. M., et al. (2016). Hypertrophic remodelling in cardiac regulatory
886 myosin light chain (MYL2) founder mutation carriers. *European Heart Journal*, 37(23).
887 <https://doi.org/10.1093/eurheartj/ehv522>
- 888 46. Olson, T. M., Karst, M. L., Whitby, F. G., & Driscoll, D. J. (2002). Myosin light chain
889 mutation causes autosomal recessive cardiomyopathy with mid-cavitary hypertrophy
890 and restrictive physiology. *Circulation*, 105(20).
891 <https://doi.org/10.1161/01.CIR.0000018444.47798.94>
- 892 47. Caleshu, C., Sakhuja, R., Nussbaum, R. L., Schiller, N. B., Ursell, P. C., Eng, C., de
893 Marco, T., McGlothlin, D., Burchard, E. G., & Rame, J. E. (2011). Furthering the link
894 between the sarcomere and primary cardiomyopathies: Restrictive cardiomyopathy
895 associated with multiple mutations in genes previously associated with hypertrophic or
896 dilated cardiomyopathy. *American Journal of Medical Genetics, Part A*, 155(9).
897 <https://doi.org/10.1002/ajmg.a.34097>
- 898 48. Osborn, D. P. S., Emrahi, L., Clayton, J., Tabrizi, M. T., Wan, A. Y. B., Maroofian, R.,
899 Yazdchi, M., Garcia, M. L. E., Galehdari, H., Hesse, C., et al. (2021). Autosomal
900 recessive cardiomyopathy and sudden cardiac death associated with variants in
901 MYL3. *Genetics in Medicine*, 23(4), 787–792. [https://doi.org/10.1038/s41436-020-](https://doi.org/10.1038/s41436-020-01028-2)
902 01028-2
- 903 49. Jaafar, N., Gómez, J., Kammoun, I., Zairi, I., Amara, W. ben, Kachboura, S., Kraiem,
904 S., Hammami, M., Iglesias, S., Alonso, B., & Coto, E. (2016). Spectrum of Mutations
905 in Hypertrophic Cardiomyopathy Genes among Tunisian Patients. *Genetic Testing and*
906 *Molecular Biomarkers*, 20(11), 674–679. <https://doi.org/10.1089/gtmb.2016.0187>
- 907 50. Ma, N., Zhang, J. Z., Itzhaki, I., Zhang, S. L., Chen, H., Haddad, F., Kitani, T., Wilson,
908 K. D., Tian, L., Shrestha, R., et al. (2018). Determining the pathogenicity of a genomic
909 variant of uncertain significance using CRISPR/Cas9 and human-induced pluripotent
910 stem cells. *Circulation*, 138(23).
911 <https://doi.org/10.1161/CIRCULATIONAHA.117.032273>
- 912 51. Janin, A., Bessière, F., Chauveau, S., Chevalier, P., & Millat, G. (2018). First
913 identification of homozygous truncating CSRFP3 variants in two unrelated cases with
914 hypertrophic cardiomyopathy. *Gene*, 676, 110–116.
915 <https://doi.org/10.1016/j.gene.2018.07.036>

- 916 52. Lipari, M., Wypasek, E., Karpinski, M., Tomkiewicz-Pajak, L., Laino, L., Binni, F.,
917 Giannarelli, D., Rubis, P., Petkow-Dimitrow, P., Undas, A., et al. (2020). Identification
918 of a variant hotspot in MYBPC3 and of a novel CSRP3 autosomal recessive alteration
919 in a cohort of Polish cases affected by hypertrophic cardiomyopathy. *Polish Archives*
920 *of Internal Medicine*. <https://doi.org/10.20452/pamw.15130>
- 921 53. Harper, A. R., Goel, A., Grace, C., Thomson, K. L., Petersen, S. E., Xu, X., Waring, A.,
922 Ormondroyd, E., Kramer, C. M., Ho, C. Y., et al. (2021). Common genetic variants and
923 modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and
924 expressivity. *Nature Genetics*, 53(2). <https://doi.org/10.1038/s41588-020-00764-0>
- 925 54. Tadros, R., Francis, C., Xu, X., Vermeer, A. M. C., Harper, A. R., Huurman, R., Kelu
926 Bisabu, K., Walsh, R., Hoorntje, E. T., et al. (2021). Shared genetic pathways
927 contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions
928 of effect. *Nature Genetics*, 53(2). <https://doi.org/10.1038/s41588-020-00762-2>
- 929 55. Pua, C. J. B., Tham, N., Chin, C. W. L., Walsh, R., Khor, C. C., Toepfer, C. N., Repetti,
930 G. G., Garfinkel, A. C., Ewoldt, J. F., Cloonan, P., et al. (2020). Genetic studies of
931 hypertrophic cardiomyopathy in singaporeans identify variants in TNNI3 and TNNT2
932 that are common in Chinese patients. *Circulation: Genomic and Precision Medicine*.
933 <https://doi.org/10.1161/CIRCGEN.119.002823>
- 934 56. Wooten, E. C., Hebl, V. B., Wolf, M. J., Sarah, R., Orr, N., Draper, I., Calvino, J. E.,
935 Navin, K., Maron, M. S., Kullo, I. J., et al. (2013). Formin Homology 2 Domain
936 Containing 3 (FHOD3) Variants Associated with Hypertrophic Cardiomyopathy.
937 *Circulation Cardiovascular Genetics*, 6(1), 10–18.
938 <https://doi.org/10.1161/CIRCGENETICS.112.965277>.Formin
- 939 57. Gómez, J., Lorca, R., Reguero, J. R., Morís, C., Martín, M., Tranche, S., Alonso, B.,
940 Iglesias, S., Alvarez, V., Díaz-Molina, B., et al. (2017). Screening of the Filamin C Gene
941 in a Large Cohort of Hypertrophic Cardiomyopathy Patients. *Circulation:*
942 *Cardiovascular Genetics*, 10(2). <https://doi.org/10.1161/CIRCGENETICS.116.001584>
- 943 58. Valdés-Mas, R., Gutiérrez-Fernández, A., Gómez, J., Coto, E., Astudillo, A., Puente,
944 D. A., Reguero, J. R., Álvarez, V., Morís, C., León, D., Martín, M., et al. (2014).
945 Mutations in filamin C cause a new form of familial hypertrophic cardiomyopathy.
946 *Nature Communications*, 5. <https://doi.org/10.1038/ncomms6326>
- 947 59. Almomani, R., Verhagen, J. M. A., Herkert, J. C., Brosens, E., van Spaendonck-
948 Zwarts, K. Y., Asimaki, A., van der Zwaag, P. A., Frohn-Mulder, I. M. E., Bertoli-Avella,
949 A. M., Boven, L. G., et al. (2016). Biallelic Truncating Mutations in ALPK3 Cause
950 Severe Pediatric Cardiomyopathy. *Journal of the American College of Cardiology*,
951 67(5), 515–525. <https://doi.org/10.1016/j.jacc.2015.10.093>
- 952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967